Brief: NanoGroup Says POLEPI Selected As Candidate For New Drug In GMP Production And Pre-Clinical Studies

Nanogroup SA

15/08/2018 09:56

Aug 15 (Reuters) - NanoGroup SA  NNG.WA :
    * SAID ON TUESDAY THAT ITS SUBSIDIARY NANOVELOS HAS
COMPLETED LAB
AND IN VIVO TESTS OF POLEPI PRODUCT AND SELECTED THE FORMULATION
OF NANOPARTICLES WITH EPIRUBICIN AS A CANDIDATE FOR PRODUCTION
IN GOOD MANUFACTURING PRACTICE (GMP) AND PRE-CLINICAL TESTS IN
GOOD LABORATORY PRACTICE (GLP) STANDARDS
    * SAYS NANOPARTICLE STRUCTURE CHARACTERISED WITH HIGH
EFFICIENCY
OF DRUG BINDING AND PROCESS REPEATABILITY HAS BEEN DEVELOPED IN
THE COURSE OF LAB TESTS
    * SAYS THE OBTAINED RESULTS CONFIRM THE ASSUMPTION OF
GRADUAL
RELEASE OF THE DRUG FROM NANOPARTICLES
    * SAYS EPIRUBICIN IS A WIDELY USED CYTOSTATIC FOR THE
TREATMENT OF
VARIOUS COMMON CANCERS
    * SAYS EPIRUBICIN IS USED BOTH IN MONOTHERAPY, AS WELL AS
COMBINATION THERAPY WITH OTHER ANTICANCER DRUGS, WHICH THE
COMPANY BELIEVES CAN RESULT IN WIDE USE OF NANOVELOS DRUG
DELIVERY SOLUTION

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM4vjs3Da
    
 Further company coverage:  NNG.WA  
   


 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))